Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.

Springfeld, Christoph; Wiecha, Christiane; Kunzmann, Romy; Heger, Ulrike; Weichert, Wilko; Langer, Rupert; Stange, Annika; Blank, Susanne; Sisic, Leila; Schmidt, Thomas; Lordick, Florian; Jäger, Dirk; Grenacher, Lars; Bruckner, Tom; Büchler, Markus W; Ott, Katja (2015). Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Annals of surgical oncology, 22(Suppl 3), pp. 905-914. Springer 10.1245/s10434-015-4617-x

[img]
Preview
Text
art%3A10.1245%2Fs10434-015-4617-x.pdf - Published Version
Available under License Publisher holds Copyright.

Download (588kB) | Preview

BACKGROUND

Perioperative chemotherapy improves survival in patients with advanced esophagogastric cancer, but the optimal treatment regimen remains unclear. More intensive chemotherapy may improve outcome, but also increase toxicity and complications.

METHODS

A total of 843 patients were included in this retrospective study and stratified in 4 groups: doublet therapy with cisplatin or oxaliplatin and 5-fluorouracil (groups A/B) or triplet therapy with additional epirubicin or taxane (groups C/D). The influence of the different neoadjuvant chemotherapy regimens on response, prognosis, and complications was assessed.

RESULTS

Clinical and pathological response were associated with longer overall survival (OS; p < 0.001). No significant differences regarding response or OS were found, but there was a trend toward better outcome in group D (taxane-containing triplet). In the subgroup of 669 patients with adenocarcinomas of the esophagogastric junction (AEG), patients who had received taxane-containing regimens had a significantly longer OS (p = 0.037), but taxane use was not an independent factor in multivariate analysis. Triple therapy with taxanes did not result in a higher complication rate or postoperative mortality.

CONCLUSIONS

Although no superior neoadjuvant chemotherapy regimen was identified for patients with esophagogastric adenocarcinoma, taxane-containing regimens should be further investigated in randomized trials, especially in patients with AEG tumors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Langer, Rupert

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1068-9265

Publisher:

Springer

Language:

English

Submitter:

Doris Haefelin

Date Deposited:

20 Jan 2016 14:06

Last Modified:

05 Dec 2022 14:51

Publisher DOI:

10.1245/s10434-015-4617-x

PubMed ID:

26001861

BORIS DOI:

10.7892/boris.74600

URI:

https://boris.unibe.ch/id/eprint/74600

Actions (login required)

Edit item Edit item
Provide Feedback